Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Berodual® Respimat® solution for inhalation

Study type: Observational

Funder types: Industry

Identifiers

NCT02231359

215.1363

Details and patient eligibility

About

Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for inhalation in patients with chronic obstructive airways disease in daily practice

Enrollment: 2,006 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women presenting with the symptoms of chronic obstructive airways disease were given Berodual® Respimat® 20/50µg/dose solution for inhalation only where this was considered necessary in medical terms
• Patients who have not been treated prior to the post-marketing surveillance study as well as patients who have been treated with Berodual® metered dose inhaler (MDI) or other respiratory medications prior to the Post-Marketing Surveillance Study could be included

Exclusion criteria

• Patients presenting with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information

Trial design

2,006 participants in 1 patient group

chronic obstructive airways disease patients

Treatment:

Drug: Berodual® Respimat® solution for inhalation